Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

X-linked severe combined immunodeficiency.

A C Church1

  • 1Glasgow Royal Infirmary, Glasgow G4 0SF.

Hospital Medicine (London, England : 1998)
|December 12, 2002
PubMed
Summary

X-linked severe combined immunodeficiency (X-SCID) is a primary immunodeficiency. Advances in molecular biology have led to new treatments for X-SCID, improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel.

Respiratory medicine·2012
Same author

Aspiration and development of subglottic stenosis in patients with Wegener's granulomatosis.

The Journal of laryngology and otology·2009
Same author

Epoprostenol use in a National Pulmonary Hypertension Centre from 1997 to 2007.

Thorax·2009
Same author

A case of refractory hypoxaemia.

Postgraduate medical journal·2008
Same author

Odd behaviour in the airport arrivals lounge--what is the diagnosis?

QJM : monthly journal of the Association of Physicians·2007
Same author

An uncommon cause of heart failure.

QJM : monthly journal of the Association of Physicians·2006

Area of Science:

  • Immunology
  • Genetics
  • Molecular Biology

Background:

  • Severe combined immunodeficiency (SCID) represents a group of rare genetic disorders.
  • It is a primary immunodeficiency affecting T-cell development and function.
  • X-linked SCID (X-SCID) is the most common form of primary immunodeficiencies in humans.

Purpose of the Study:

  • This review focuses on the molecular underpinnings of X-linked severe combined immunodeficiency.
  • It highlights recent therapeutic advancements for X-SCID.

Main Methods:

  • Review of current literature on molecular biology techniques.
  • Analysis of recent clinical trial data for X-SCID treatments.
  • Synthesis of information on genetic basis and therapeutic strategies.

Main Results:

  • Detailed explanation of the molecular basis of X-SCID.
  • Overview of novel therapeutic approaches, including gene therapy and hematopoietic stem cell transplantation.
  • Discussion of the efficacy and safety of new treatments.

Conclusions:

  • Molecular insights have revolutionized X-SCID treatment.
  • New therapies offer improved prospects for patients with X-linked severe combined immunodeficiency.
  • Continued research is crucial for further optimizing X-SCID management.

Related Experiment Videos